Los Angeles Capital Management
PGNX

Los Angeles Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Los Angeles Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-28,770
Closed -$171K – 1455
2017
Q4 		$171K Sell
28,770
-60,210
-68% -$366K ﹤0.01% 1284
2017
Q3 		$655K Buy
88,980
+73,010
+457% +$464K ﹤0.01% 940
2017
Q2 		$108K Buy
+15,970
New +$118K ﹤0.01% 1177
2014
Q2 		– Sell
-54,170
Closed -$222K – 1322
2014
Q1 		$222K Buy
+54,170
New +$277K ﹤0.01% 1158

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Los Angeles Capital Management's PGNX Position: Q1 2018 in Review

Los Angeles Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2018, closing a stake of 28,770 shares — an estimated $171K sold.

Los Angeles Capital Management first reported a position in PGNX in Q1 2014 and held it in 4 quarters. The position peaked at $655K in Q3 2017. 152 funds tracked by Wall St. Rank hold PGNX as of Q1 2018.

  • Los Angeles Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Los Angeles Capital Management sold 28,770 Progenics Pharmaceuticals Inc shares in Q1 2018, an estimated $171K.
  • Los Angeles Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2014 and held it in 4 quarters.
  • Los Angeles Capital Management's Progenics Pharmaceuticals Inc position peaked at $655K in Q3 2017.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2018.

Based on Los Angeles Capital Management's 13F filing for Q1 2018, filed 27 Apr 2018.